EASL-ERN Clinical Practice Guidelines on Wilson’s Disease
Clinical knowledge base written and curated by GastroAGI Team from primary medical literatureLast updated May 1, 2025
As of October 2023, the European Association for the Study of the Liver (EASL) and the European Reference Network (ERN) for Rare Liver Diseases have provided Clinical Practice Guidelines (CPGs) for Wilson’s Disease (WD) to guide healthcare professionals in diagnosing, managing, and treating this rare genetic disorder. Below is a detailed summary of the key recommendations and insights from these guidelines:
1. Overview of Wilson’s Disease
- Definition: Wilson’s Disease is an autosomal recessive disorder caused by mutations in the ATP7B gene, leading to impaired copper metabolism and accumulation in the liver, brain, and other organs.
- Prevalence: Approximately 1 in 30,000–50,000 individuals globally, with regional differences in common mutations.
- Clinical Manifestations: Hepatic, neurological, and psychiatric symptoms dominate, with variable severity.
2. Diagnosis
Clinical and Biochemical Evaluation
- Kayser–Fleischer Rings: A hallmark sign, present in ~95% of neurological cases and ~50% of hepatic cases, detected via slit-lamp examination.
- Serum Ceruloplasmin: Typically <20 mg/dL, but not specific; low levels are supportive of WD.
- 24-hour Urinary Copper Excretion: Values >100 µg/24h are diagnostic.
- Liver Copper Content: >250 µg/g dry weight on biopsy confirms diagnosis.
- Relative Exchangeable Copper (REC): >15% strongly supports WD diagnosis, especially in acute liver failure cases.
Genetic Testing
- ATP7B Gene Analysis: Recommended for confirmation, especially when biochemical tests are inconclusive. Next-generation sequencing identifies >85% of pathogenic mutations.
- Family Screening: First-degree relatives should undergo ceruloplasmin, urinary copper, and genetic testing due to a 25% risk of WD.
Diagnostic Scoring
- Leipzig Score: A structured scoring system integrating clinical, biochemical, and genetic findings to confirm WD.
Imaging
- Brain MRI: Useful for neurological WD; findings include T2 hyperintensities in the basal ganglia and the “face of the giant panda” sign.
- Liver Biopsy: Confirms copper overload but may yield false negatives due to uneven copper distribution.
3. Management
Pharmacological Treatment
- Chelating Agents:
- D-Penicillamine: Promotes copper excretion; first-line therapy for hepatic WD.
- Trientine: An alternative chelator with fewer side effects.
- Zinc Salts: Blocks intestinal copper absorption; suitable for maintenance therapy or asymptomatic cases.
- Combination Therapy: In some cases, chelators and zinc may be combined under expert supervision.
Liver Transplantation
- Indications:
- Wilsonian acute liver failure (ALF).
- End-stage cirrhosis unresponsive to medical therapy.
- Outcome: Effectively cures copper metabolism abnormalities and prevents further organ damage.
Neurological and Psychiatric Management
- Unified Wilson’s Disease Rating Scale (UWDRS): Recommended for monitoring neurological severity in adults and children >10 years old.
- Psychiatric Care: Depression, anxiety, and behavioral changes should be addressed with appropriate therapy.
Monitoring Therapy
- Regular follow-up is crucial to ensure:
- Adequate copper balance (avoiding over- or under-treatment).
- Compliance with lifelong treatment.
- Monitoring of urinary copper levels and liver enzymes.
4. Special Considerations
Acute Liver Failure (ALF)
- Diagnostic tests like serum ceruloplasmin and urinary copper may be less reliable in ALF. Genetic testing and relative exchangeable copper are preferred for accuracy.
- Coombs-negative hemolysis, high bilirubin, low alkaline phosphatase, and modest ALT/AST elevations are characteristic laboratory findings.
Pediatric Presentation
- In children, WD may present as asymptomatic transaminase elevation, hepatomegaly, or acute hepatitis. Neurological symptoms are rare but may include subtle tremor or ataxia.
Differential Diagnosis
- WD should be distinguished from autoimmune hepatitis, viral hepatitis, metabolic-associated steatotic liver disease (MASLD), hemochromatosis, alpha-1 antitrypsin deficiency, and cholestatic liver diseases.
5. Multidisciplinary Approach
- Team Involvement: Management requires collaboration among hepatologists, neurologists, psychiatrists, geneticists, and dietitians.
- Family Support: Genetic counseling and psychological support for patients and families are essential.
6. Key Recommendations
- Early Diagnosis: Prioritize early recognition using the Leipzig score, biochemical tests, and genetic testing to prevent irreversible organ damage.
- Lifelong Treatment: Ensure adherence to pharmacological therapy and monitoring to improve survival and quality of life.
- Family Screening: Early detection in siblings and first-degree relatives prevents disease progression.
- Liver Transplantation: Consider transplantation in cases of acute liver failure or end-stage liver disease.
Conclusion
The EASL-ERN Clinical Practice Guidelines emphasize the importance of early diagnosis, structured management, and lifelong treatment of Wilson’s Disease to prevent irreversible hepatic and neurological damage. A multidisciplinary approach and family screening are crucial to optimizing outcomes and improving the quality of life for affected individuals.
For further details, refer to the full EASL-ERN guidelines or consult with specialists in rare liver diseases.
